Skip to main content
. 2020 Oct 13;3(10):e2020312. doi: 10.1001/jamanetworkopen.2020.20312

Figure 1. Association of Cyclin-Dependent Kinases 4 and 6 (CDK4/6) Inhibitors Plus Endocrine Therapy (ET) vs ET Alone With Overall Survival Among Women With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer.

Figure 1.

An inverse-weighting method and a fixed-effect model were used in the analysis. The size of the data markers (squares) corresponds to the weight of the study in the meta-analysis. HR indicates hazard ratio.